Analysis Life Sciences Thank You What We Expect the FDA to do in October 2023
Agency IQ
SEPTEMBER 29, 2023
An avalanche of new legislation: Speaking of Congress, the House and Senate are back in session as of mid-September and we have already noticed a lot of legislative interest in the FDA – probably about two dozen bills related to drug shortages, generic drug competition, supply chain security, opioids, medical device recalls and orphan drug products.
Let's personalize your content